,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting stock held by non affiliates of the registrant was approximately $91,942,474,363 at June 30, 2021. There were 377,544,686 shares outstanding of the registrant's common stock, $0.10 par value, on January 31, 2022.","91,942,474,363",['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,syk,"The aggregate market value of the voting stock held by non affiliates of the registrant was approximately $91,942,474,363 at June 30, 2021.","approximately $91,942,474,363",MONEY,"The aggregate market value of the voting stock held by non affiliates of the registrant was approximately $91,942,474,363 at June 30, 2021.","['aggregate market value of voting stock', 'non affiliates of registrant', 'aggregate market value', 'voting stock', 'non affiliates']","['voting stock', 0.2911767363548279, 'What is approximately $91,942,474,363 ?', 'voting stock']",voting stock,0.2911767363548279,"What is approximately $91,942,474,363 ?",voting stock,aggregate market value of voting stock held by non affiliates
1,"The aggregate market value of the voting stock held by non affiliates of the registrant was approximately $91,942,474,363 at June 30, 2021. There were 377,544,686 shares outstanding of the registrant's common stock, $0.10 par value, on January 31, 2022.","377,544,686","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,syk,"There were 377,544,686 shares outstanding of the registrant’s common stock, $0.10 par value, on January 31, 2022.","377,544,686",CARDINAL,"There were 377,544,686 shares outstanding of the registrant’s common stock, $0.10 par value, on January 31, 2022.",['registrant common stock'],"['registrant common stock', 0.9828571081161499, 'how many registrant common stock ?', '377,544,686']",registrant common stock,0.98285710811615,how many registrant common stock ?,"377,544,686",Shares of common stock outstanding
2,"Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.",30,"['Property, plant and equipment useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,syk,Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.,three to 30 years,DATE,Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.,"['straight line method over estimated useful lives', 'estimated useful lives of years', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives']","['straight line method over estimated useful lives', 0.8066624999046326, 'what is straight line method over estimated useful lives ?', 'three to 30 years']",straight line method over estimated useful lives,0.8066624999046326,what is straight line method over estimated useful lives ?,three to 30 years,the estimated useful lives of buildings and improvements
3,"Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.",15,"['Property, plant and equipment useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,syk,Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.,three to 15 years,DATE,Depreciation is generally computed by the straight line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.,"['straight line method over estimated useful lives', 'estimated useful lives of years', 'years for buildings', 'years for machinery', 'straight line method', 'useful lives']","['machinery and equipment', 0.9223803877830505, 'What is three to 15 years ?', 'machinery and equipment']",machinery and equipment,0.9223803877830504,What is three to 15 years ?,machinery and equipment,machinery and equipment depreciation
4,"The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below.",40,"['Finite lived intangible asset, useful life']",us-gaap_FiniteLivedIntangibleAssetUsefulLife,durationItemType,syk,Intangible assets with determinable useful lives are amortized on a straight line basis over their estimated useful lives of four to 40 years.,four to 40 years,DATE,Intangible assets with determinable useful lives are amortized on a straight line basis over their estimated useful lives of four to 40 years.,"['Intangible assets with determinable useful lives', 'line basis over estimated useful lives', 'estimated useful lives of years', 'Intangible assets', 'determinable useful lives', 'line basis', 'useful lives']","['Intangible assets with determinable useful lives', 0.8488178253173828, 'what is Intangible assets with determinable useful lives ?', 'four to 40 years']",Intangible assets with determinable useful lives,0.8488178253173828,what is Intangible assets with determinable useful lives ?,four to 40 years,Intangible assets useful lives
5,"Share Based Compensation: Share based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long term incentive plans to certain key employees and non employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments.",10,['Vesting period'],us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1,durationItemType,syk,The options are granted for periods of up to 10 years and become exercisable in varying installments.,up to 10 years,DATE,The options are granted for periods of up to 10 years and become exercisable in varying installments.,['periods of years'],"['periods of years', 0.6482943296432495, 'what is periods of years ?', 'up to 10 years']",periods of years,0.6482943296432495,what is periods of years ?,up to 10 years,granted for periods
6,"We grant RSUs to key employees and non employee directors and PSUs to certain key employees under our long term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one third increments over a three year period and are settled in stock. PSUs are earned over a three year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre established goals in that three year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.",three year,['Performance period'],syk_SharebasedCompensationArrangementbySharebasedPaymentAwardPerformancePeriod,durationItemType,syk,RSUs generally vest in one third increments over a three year period and are settled in stock.,three year,DATE,RSUs generally vest in one third increments over a three year period and are settled in stock.,"['third increments', 'year period']","['', 0, '', '']",,0.0,,,one third increments
7,"We grant RSUs to key employees and non employee directors and PSUs to certain key employees under our long term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one third increments over a three year period and are settled in stock. PSUs are earned over a three year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre established goals in that three year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.",three year,['Vesting period'],us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1,durationItemType,syk,RSUs generally vest in one third increments over a three year period and are settled in stock.,three year,DATE,RSUs generally vest in one third increments over a three year period and are settled in stock.,"['third increments', 'year period']","['', 0, '', '']",,0.0,,,one third increments
8,"We grant RSUs to key employees and non employee directors and PSUs to certain key employees under our long term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one third increments over a three year period and are settled in stock. PSUs are earned over a three year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre established goals in that three year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.",three year,['Vesting period'],us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1,durationItemType,syk,RSUs generally vest in one third increments over a three year period and are settled in stock.,three year,DATE,RSUs generally vest in one third increments over a three year period and are settled in stock.,"['third increments', 'year period']","['', 0, '', '']",,0.0,,,one third increments
9,"Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2021 less than 10% of our sales were recognized as services transferred over time. Refer to Note 1 for further discussion on our revenue recognition policies.",10,['Percentage of sales recognized as services over time'],syk_PercentageofServiceRevenueRecognizeoverTime,percentItemType,syk,In 2021 less than 10% of our sales were recognized as services transferred over time.,10%,PERCENT,In 2021 less than 10% of our sales were recognized as services transferred over time.,['% of sales'],"['% of sales', 0.6543945074081421, 'what is % of sales ?', 'less than 10%']",% of sales,0.6543945074081421,what is % of sales ?,less than 10%,sales recognized as services transferred over time
10,"Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",529,['Contract liabilities'],us-gaap_ContractWithCustomerLiability,monetaryItemType,syk,"Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",$529,MONEY,"Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",['contract liabilities'],"['contract liabilities', 0.9104336500167847, 'what is contract liabilities ?', '$529 and $416']",contract liabilities,0.9104336500167848,what is contract liabilities ?,$529 and $416,"Contract liabilities on December 31, 2021

Entity:
$416
Phrase:
Contract liabilities on December 31, 2020"
11,"Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",416,['Contract liabilities'],us-gaap_ContractWithCustomerLiability,monetaryItemType,syk,"Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",$416,MONEY,"Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.",['contract liabilities'],"['contract liabilities', 0.9104336500167847, 'what is contract liabilities ?', '$529 and $416']",contract liabilities,0.9104336500167848,what is contract liabilities ?,$529 and $416,Contract liabilities
12,"On December 31, 2021 the aggregate difference between the cost and fair value of available for sale marketable securities was nominal. Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",68,"['Marketable securities, gain']",us-gaap_MarketableSecuritiesGainLoss,monetaryItemType,syk,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",$68,MONEY,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income , net.",['other income'],"['Interest and marketable securities income', 0.8273951411247253, 'What is $68 ?', 'Interest and marketable securities income']",Interest and marketable securities income,0.8273951411247253,What is $68 ?,Interest and marketable securities income,Interest and marketable securities income
13,"On December 31, 2021 the aggregate difference between the cost and fair value of available for sale marketable securities was nominal. Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",102,"['Marketable securities, gain']",us-gaap_MarketableSecuritiesGainLoss,monetaryItemType,syk,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",$102,MONEY,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income , net.",['other income'],"['Interest and marketable securities income', 0.7041362524032593, 'What is $102 ?', 'Interest and marketable securities income']",Interest and marketable securities income,0.7041362524032593,What is $102 ?,Interest and marketable securities income,Interest and marketable securities income
14,"On December 31, 2021 the aggregate difference between the cost and fair value of available for sale marketable securities was nominal. Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",155,"['Marketable securities, gain']",us-gaap_MarketableSecuritiesGainLoss,monetaryItemType,syk,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.",$155,MONEY,"Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income , net.",['other income'],"['Interest and marketable securities income', 0.3965867757797241, 'What is $155 ?', 'Interest and marketable securities income']",Interest and marketable securities income,0.3965867757797241,What is $155 ?,Interest and marketable securities income,Interest and marketable securities income
15,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.",2.0,"['Notional amount', 'Derivative, notional amount']",us-gaap_DerivativeNotionalAmount,monetaryItemType,syk,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros.",$€2.0 billion and,MONEY,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros.","['portion of investments', 'portion', 'entities with functional currencies', 'certain forward currency contracts', 'net investment hedges', 'functional currencies']","['', 0, '', '']",,0.0,,,forward currency contracts
16,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.",1.5,"['Notional amount', 'Derivative, notional amount']",us-gaap_DerivativeNotionalAmount,monetaryItemType,syk,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros.",$€1.5 billion,MONEY,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros.","['portion of investments', 'portion', 'entities with functional currencies', 'certain forward currency contracts', 'net investment hedges', 'functional currencies']","['forward currency contracts', 0.17683841288089752, 'What is $€1.5 billion ?', 'forward currency contracts']",forward currency contracts,0.1768384128808975,What is $€1.5 billion ?,forward currency contracts,Forward currency contracts
17,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.",4.4,['Notional amount'],syk_DerivativeNotionalAmount1,monetaryItemType,syk,"In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries.",$€4.4 billion,MONEY,"In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries.","['addition to derivative financial instruments', 'portions of investment', 'investment in certain international subsidiaries', 'derivative financial instruments', 'net investment hedges', 'senior unsecured notes', 'net investment hedges', 'certain international subsidiaries']","['senior unsecured notes', 0.5194828510284424, 'What is $€4.4 billion ?', 'senior unsecured notes']",senior unsecured notes,0.5194828510284424,What is $€4.4 billion ?,senior unsecured notes,Senior unsecured notes
18,"We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.",4.4,['Notional amount'],syk_DerivativeNotionalAmount1,monetaryItemType,syk,"In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries.",$€4.4 billion,MONEY,"In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries.","['addition to derivative financial instruments', 'portions of investment', 'investment in certain international subsidiaries', 'derivative financial instruments', 'net investment hedges', 'senior unsecured notes', 'net investment hedges', 'certain international subsidiaries']","['senior unsecured notes', 0.5194828510284424, 'What is $€4.4 billion ?', 'senior unsecured notes']",senior unsecured notes,0.5194828510284424,What is $€4.4 billion ?,senior unsecured notes,Senior unsecured notes
19,"On December 31, 2021 the total after tax gain (loss) in AOCI related to designated net investment hedges was ($34).",34,[],us-gaap_NetInvestmentHedgeDerivativeAssetsAtFairValue,monetaryItemType,syk,"On December 31, 2021 the total after tax gain (loss) in AOCI related to designated net investment hedges was ($34).",$34,MONEY,"On December 31, 2021 the total after tax gain  in AOCI related to designated net investment hedges was $34.","['total after tax gain', 'tax gain in AOCI', 'tax gain', 'net investment hedges']","['tax gain in AOCI', 0.9504289031028748, 'what is tax gain in AOCI ?', '$34']",tax gain in AOCI,0.9504289031028748,what is tax gain in AOCI ?,$34,After tax gain in AOCI
20,"Pretax gains (losses) on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of December 31, 2021. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge",9,['Cash flow hedge gain  to be reclassified within twelve months'],us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths,monetaryItemType,syk,"Pretax gains (losses) on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of December 31, 2021.",$9,MONEY,"Pretax gains  on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income , net in earnings within 12 months as of December 31, 2021.","['Pretax gains on derivatives', 'flow hedges', 'net investment hedges', 'net in earnings', 'earnings within months', 'net', 'Pretax gains', 'flow hedges']","['cash flow hedges', 0.8821418881416321, 'What is $9 ?', 'cash flow hedges']",cash flow hedges,0.8821418881416321,What is $9 ?,cash flow hedges,"Derivatives designated as cash flow hedges

Entity:
$37
Phrase:
Net investment hedges"
21,"Pretax gains (losses) on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of December 31, 2021. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge",37,"['Derivatives used in Net Investment Hedge, Gain , Reclassified to Earnings, Net of Tax', 'Net investment hedges expected to be reclassified to cost of sales and other income']",us-gaap_DerivativesUsedInNetInvestmentHedgeGainLossReclassifiedToEarningsNetOfTax,monetaryItemType,syk,"Pretax gains (losses) on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of December 31, 2021.",$37,MONEY,"Pretax gains  on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income , net in earnings within 12 months as of December 31, 2021.","['Pretax gains on derivatives', 'flow hedges', 'net investment hedges', 'net in earnings', 'earnings within months', 'net', 'Pretax gains', 'flow hedges']","['net investment hedges', 0.8713713884353638, 'What is $37 ?', 'net investment hedges']",net investment hedges,0.8713713884353638,What is $37 ?,net investment hedges,Derivatives designated as cash flow hedges
22,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur. Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of December 31, 2021. The cash flow effect of interest rate hedges is recorded in cash flow from operations.",11,['Reclassification of gain  from AOCI to earnings'],us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax,monetaryItemType,syk,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.",$11,MONEY,"In 2021 a loss of $11 was reclassified from AOCI to other income , net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.","['loss', 'net in earnings', 'termination', 'notional amounts', 'other income', 'rate swaps', 'notional amounts', 'flow hedges', 'original debt issuances']","['loss', 0.5782878994941711, 'what is loss ?', '$11']",loss,0.5782878994941711,what is loss ?,$11,Loss from AOCI to other income
23,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur. Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of December 31, 2021. The cash flow effect of interest rate hedges is recorded in cash flow from operations.",750,"['Notional amount', 'Derivative, notional amount']",us-gaap_DerivativeNotionalAmount,monetaryItemType,syk,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.",$750,MONEY,"In 2021 a loss of $11 was reclassified from AOCI to other income , net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.","['loss', 'net in earnings', 'termination', 'notional amounts', 'other income', 'rate swaps', 'notional amounts', 'flow hedges', 'original debt issuances']","['notional amounts', 0.9698983430862427, 'what is notional amounts ?', '$750']",notional amounts,0.9698983430862428,what is notional amounts ?,$750,Forward starting interest rate swaps
24,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur. Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of December 31, 2021. The cash flow effect of interest rate hedges is recorded in cash flow from operations.",5,['Cash flow hedge gain  to be reclassified within twelve months'],us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths,monetaryItemType,syk,"In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.",$750,MONEY,"In 2021 a loss of $11 was reclassified from AOCI to other income , net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur.","['loss', 'net in earnings', 'termination', 'notional amounts', 'other income', 'rate swaps', 'notional amounts', 'flow hedges', 'original debt issuances']","['notional amounts', 0.9698983430862427, 'what is notional amounts ?', '$750']",notional amounts,0.9698983430862428,what is notional amounts ?,$750,Forward starting interest rate swaps
25,"We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.",393,['Aggregate purchase price of acquisitions'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,syk,"The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.",$393,MONEY,"The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.","['aggregate purchase price of acquisitions', 'net of cash', 'aggregate purchase price']","['aggregate purchase price', 0.5021618604660034, 'what is aggregate purchase price ?', '$393 and $4,304']",aggregate purchase price,0.5021618604660034,what is aggregate purchase price ?,"$393 and $4,304","2021 acquisitions, net of cash acquired"
26,"We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.","4,304",['Aggregate purchase price of acquisitions'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,syk,"The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.","$4,304",MONEY,"The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.","['aggregate purchase price of acquisitions', 'net of cash', 'aggregate purchase price']","['aggregate purchase price', 0.5021618604660034, 'what is aggregate purchase price ?', '$393 and $4,304']",aggregate purchase price,0.5021618604660034,what is aggregate purchase price ?,"$393 and $4,304",Acquisitions purchase price
27,"In September 2021 we completed the acquisition of Gauss Surgical, Inc. (Gauss) for $120 in cash and up to $40 in future milestone payments. Gauss is a medical device company that has developed Triton, an artificial intelligence enabled platform for real time monitoring of blood loss during surgery. Gauss is part of our Instruments business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition is not deductible for tax purposes.",120,['Aggregate purchase price of acquisitions'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,syk,"In September 2021 we completed the acquisition of Gauss Surgical, Inc. (Gauss) for $120 in cash and up to $40 in future milestone payments.",$120,MONEY,"In September 2021 we completed the acquisition of Gauss Surgical, Inc.  for $120 in cash and up to $40 in future milestone payments.","['acquisition of Gauss Surgical', 'future milestone payments']","['cash', 0.8685709834098816, 'What is $120 ?', 'cash']",cash,0.8685709834098816,What is $120 ?,cash,"Cash acquisition of Gauss Surgical, Inc."
28,"In September 2021 we completed the acquisition of Gauss Surgical, Inc. (Gauss) for $120 in cash and up to $40 in future milestone payments. Gauss is a medical device company that has developed Triton, an artificial intelligence enabled platform for real time monitoring of blood loss during surgery. Gauss is part of our Instruments business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition is not deductible for tax purposes.",40,['Future regulatory and commercial milestones'],syk_BusinessCombinationContingentConsiderationFutureMilestonePayments,monetaryItemType,syk,"In September 2021 we completed the acquisition of Gauss Surgical, Inc. (Gauss) for $120 in cash and up to $40 in future milestone payments.",up to $40,MONEY,"In September 2021 we completed the acquisition of Gauss Surgical, Inc.  for $120 in cash and up to $40 in future milestone payments.","['acquisition of Gauss Surgical', 'future milestone payments']","['future milestone payments', 0.4635542631149292, 'What is up to $40 ?', 'future milestone payments']",future milestone payments,0.4635542631149292,What is up to $40 ?,future milestone payments,future milestone payments
29,"In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes). Wright is a global medical device company focused on extremities and biologics. Wright is part of our Trauma and Extremities business within Orthopaedics and Spine. Goodwill attributable to the acquisition is not deductible for tax purposes.",4.1,['Aggregate purchase price of acquisitions'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,syk,"In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes).",$4.1 billion,MONEY,"In November 2020 we completed the acquisition of Wright Medical Group N.V.  for $30.75 per share, or an aggregate purchase price of $4.1 billion $5.6 billion including convertible notes.","['acquisition of Wright Medical Group N.V.', 'aggregate purchase price', 'convertible notes']","['aggregate purchase price', 0.6616417169570923, 'what is aggregate purchase price ?', '$4.1 billion']",aggregate purchase price,0.6616417169570923,what is aggregate purchase price ?,$4.1 billion,"Wright Medical Group N.V. acquisition

Entity: 
$5.6 billion
Phrase: 
Wright Medical Group N.V. acquisition including convertible notes"
30,"In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes). Wright is a global medical device company focused on extremities and biologics. Wright is part of our Trauma and Extremities business within Orthopaedics and Spine. Goodwill attributable to the acquisition is not deductible for tax purposes.",5.6,"['Purchase price of acquisitions, including convertible notes']",syk_BusinessCombinationConsiderationTransferredIncludingConvertibleNotes,monetaryItemType,syk,"In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes).",$5.6 billion,MONEY,"In November 2020 we completed the acquisition of Wright Medical Group N.V.  for $30.75 per share, or an aggregate purchase price of $4.1 billion $5.6 billion including convertible notes.","['acquisition of Wright Medical Group N.V.', 'aggregate purchase price', 'convertible notes']","['convertible notes', 0.3293096423149109, 'What is $5.6 billion ?', 'convertible notes']",convertible notes,0.3293096423149109,What is $5.6 billion ?,convertible notes,Including convertible notes
31,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities.,1.625,['Stated interest rate'],us-gaap_DebtInstrumentInterestRateStatedPercentage,percentItemType,syk,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,1.625%,PERCENT,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,"['note holders In November', 'Wright acquisition']","['convertible notes', 0.2768576145172119, 'What is 1.625% ?', 'convertible notes']",convertible notes,0.2768576145172119,What is 1.625% ?,convertible notes,"Convertible notes

Entity:
2.25%
Phrase:
Convertible notes"
32,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities.,2.25,['Stated interest rate'],us-gaap_DebtInstrumentInterestRateStatedPercentage,percentItemType,syk,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,2.25%,PERCENT,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,"['note holders In November', 'Wright acquisition']","['convertible notes', 0.8834841847419739, 'What is 2.25% ?', 'convertible notes']",convertible notes,0.8834841847419739,What is 2.25% ?,convertible notes,Convertible notes assumed in the Wright acquisition
33,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities.,864,['Repayments of long term debt'],us-gaap_RepaymentsOfLongTermDebt,monetaryItemType,syk,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,$864,MONEY,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,"['note holders In November', 'Wright acquisition']","['convertible notes', 0.3404650092124939, 'What is $864 ?', 'convertible notes']",convertible notes,0.3404650092124939,What is $864 ?,convertible notes,1.625% convertible notes assumed in the Wright acquisition
34,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities.,576,['Repayments of long term debt'],us-gaap_RepaymentsOfLongTermDebt,monetaryItemType,syk,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,$576,MONEY,In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576.,"['note holders In November', 'Wright acquisition']","['convertible notes', 0.6192454695701599, 'What is $576 ?', 'convertible notes']",convertible notes,0.6192454695701599,What is $576 ?,convertible notes,2.25% convertible notes
35,"In January 2022 we announced a definitive merger agreement to acquire all of the issued and outstanding common shares of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of approximately $3.1 billion (including convertible notes). Pursuant to the agreement we commenced a tender offer to purchase all of the outstanding shares of common stock of Vocera for $79.25 per share in cash. The boards of directors of both Stryker and Vocera have unanimously approved the transaction. We expect the acquisition to close in the first quarter of 2022, subject to completion of the tender offer and other customary conditions. Vocera has emerged as a leading platform in the digital care coordination and communication category. Following closing, we plan to integrate Vocera into our Medical business within MedSurg and Neurotechnology.",3.1,['Aggregate purchase price of acquisitions'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,syk,"In January 2022 we announced a definitive merger agreement to acquire all of the issued and outstanding common shares of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of approximately $3.1 billion (including convertible notes).",approximately $3.1 billion,MONEY,"In January 2022 we announced a definitive merger agreement to acquire all of the issued and outstanding common shares of Vocera Communications, Inc.  for $79.25 per share, or an aggregate purchase price of approximately $3.1 billion .","['issued common shares of Vocera Communications', 'aggregate purchase price', 'definitive merger agreement', 'issued common shares']","['an aggregate purchase price', 0.4978172183036804, 'What is approximately $3.1 billion ?', 'an aggregate purchase price']",an aggregate purchase price,0.4978172183036804,What is approximately $3.1 billion ?,an aggregate purchase price,definitive merger agreement
36,"We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.",103,['Charges during period'],us-gaap_LossContingencyLossInPeriod,monetaryItemType,syk,"In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems.",$103,MONEY,"In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems.","['charges', 'payments']","['charges', 0.7461867928504944, 'what is charges ?', '$103']",charges,0.7461867928504944,what is charges ?,$103,"2021 charges

Entity: 
$221
Phrase: 
2021 payments"
37,"We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.",221,['Payments during period'],us-gaap_LossContingencyAccrualPayments,monetaryItemType,syk,"In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems.",$221,MONEY,"In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems.","['charges', 'payments']","['Rejuvenate and ABG II Modular Neck hip stems', 0.38123223185539246, 'What is $221 ?', 'Rejuvenate and ABG II Modular Neck hip stems']",Rejuvenate and ABG II Modular Neck hip stems,0.3812322318553924,What is $221 ?,Rejuvenate and ABG II Modular Neck hip stems,Rejuvenate and ABG II Modular Neck hip stems
38,"We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.",385,['Estimate of possible loss'],us-gaap_LossContingencyEstimateOfPossibleLoss,monetaryItemType,syk,"Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520.",approximately $385 to $520,MONEY,"Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520.","['remaining range of probable loss', 'probable loss']","['probable loss related to recall matters', 0.2861655354499817, 'What is approximately $385 to $520 ?', 'probable loss related to recall matters']",probable loss related to recall matters,0.2861655354499817,What is approximately $385 to $520 ?,probable loss related to recall matters,probable loss related to recall matters globally
39,"We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.",520,['Estimate of possible loss'],us-gaap_LossContingencyEstimateOfPossibleLoss,monetaryItemType,syk,"Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520.",approximately $385 to $520,MONEY,"Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520.","['remaining range of probable loss', 'probable loss']","['probable loss related to recall matters', 0.2861655354499817, 'What is approximately $385 to $520 ?', 'probable loss related to recall matters']",probable loss related to recall matters,0.2861655354499817,What is approximately $385 to $520 ?,probable loss related to recall matters,probable loss related to recall matters globally
40,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",133,['Lease expense'],us-gaap_OperatingLeaseExpense,monetaryItemType,syk,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",$133,MONEY,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",['lease expense'],"['Operating lease expense', 0.8307400345802307, 'What is $133 ?', 'Operating lease expense']",Operating lease expense,0.8307400345802307,What is $133 ?,Operating lease expense,Operating lease expense
41,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",130,['Lease expense'],us-gaap_OperatingLeaseExpense,monetaryItemType,syk,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",$130,MONEY,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",['lease expense'],"['Operating lease expense', 0.7891679406166077, 'What is $130 ?', 'Operating lease expense']",Operating lease expense,0.7891679406166077,What is $130 ?,Operating lease expense,Operating lease expense
42,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",133,['Lease expense'],us-gaap_OperatingLeaseExpense,monetaryItemType,syk,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",$133,MONEY,"Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.",['lease expense'],"['Operating lease expense', 0.8307400345802307, 'What is $133 ?', 'Operating lease expense']",Operating lease expense,0.8307400345802307,What is $133 ?,Operating lease expense,Operating lease expense
43,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10. No shares of preferred stock were outstanding on December 31, 2021.","1,000,500,000","['Common and Preferred Stock, shares authorized']",syk_CommonAndPreferredStockSharesAuthorized,sharesItemType,syk,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","up to 1,000,500,000",CARDINAL,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","['aggregate number of shares', 'shares of classes', 'classes of stock', 'shares of preferred stock', 'shares of common stock', 'par value', 'aggregate number', 'common stock', 'par value']","['aggregate number of shares of all classes of stock', 0.4486861824989319, 'What is up to 1,000,500,000 ?', 'aggregate number of shares of all classes of stock']",aggregate number of shares of all classes of stock,0.4486861824989319,"What is up to 1,000,500,000 ?",aggregate number of shares of all classes of stock,authorized to issue
44,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10. No shares of preferred stock were outstanding on December 31, 2021.","500,000","['Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,syk,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","up to 1,000,500,000",CARDINAL,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","['aggregate number of shares', 'shares of classes', 'classes of stock', 'shares of preferred stock', 'shares of common stock', 'par value', 'aggregate number', 'common stock', 'par value']","['aggregate number of shares of all classes of stock', 0.4486861824989319, 'What is up to 1,000,500,000 ?', 'aggregate number of shares of all classes of stock']",aggregate number of shares of all classes of stock,0.4486861824989319,"What is up to 1,000,500,000 ?",aggregate number of shares of all classes of stock,Authorized to issue
45,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10. No shares of preferred stock were outstanding on December 31, 2021.","1,000,000,000","['Common stock, authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,syk,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","1,000,000,000",CARDINAL,"The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10.","['aggregate number of shares', 'shares of classes', 'classes of stock', 'shares of preferred stock', 'shares of common stock', 'par value', 'aggregate number', 'common stock', 'par value']","['shares of common stock', 0.8543987274169922, 'What is 1,000,000,000 ?', 'shares of common stock']",shares of common stock,0.8543987274169922,"What is 1,000,000,000 ?",shares of common stock,Authorized to issue common stock
46,"We made no repurchases of shares in 2021. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price and other factors and are subject to regulatory considerations. Purchases are made from time to time in the open market, in privately negotiated transactions or otherwise. On December 31, 2021 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033.","1,033",['Remaining shares authorized to be repurchased'],us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1,monetaryItemType,syk,"On December 31, 2021 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033.","$1,033",MONEY,"On December 31, 2021 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033.","['total dollar value of shares', 'total dollar value', 'repurchase program']","['total dollar value of shares', 0.9648600816726685, 'what is total dollar value of shares ?', '$1,033']",total dollar value of shares,0.9648600816726683,what is total dollar value of shares ?,"$1,033",Shares authorized repurchase program
47,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.",25,['Capital shares reserved for future issuance'],us-gaap_CommonStockCapitalSharesReservedForFutureIssuance,sharesItemType,syk,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.",25 million and 28 million,CARDINAL,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.","['future compensation grants of common stock', 'future compensation grants', 'common stock']","['future compensation grants', 0.850342869758606, 'how many future compensation grants ?', '25 million and 28 million']",future compensation grants,0.850342869758606,how many future compensation grants ?,25 million and 28 million,Compensation grants of common stock
48,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.",28,['Capital shares reserved for future issuance'],us-gaap_CommonStockCapitalSharesReservedForFutureIssuance,sharesItemType,syk,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.",25 million and 28 million,CARDINAL,"Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.","['future compensation grants of common stock', 'future compensation grants', 'common stock']","['future compensation grants', 0.850342869758606, 'how many future compensation grants ?', '25 million and 28 million']",future compensation grants,0.850342869758606,how many future compensation grants ?,25 million and 28 million,Shares of common stock reserved for future compensation grants
49,"The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $253, $258, and $294 in 2021, 2020 and 2019. Exercise prices for options outstanding ranged from $53.60 to $270.94 on December 31, 2021. On December 31, 2021 there was $101 of unrecognized compensation cost related to nonvested stock options granted under the long term incentive plans; that cost is expected to be recognized over the weighted average period of approximately 1.5 years.",253,['Aggregate intrinsic value of options exercised'],us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue,monetaryItemType,syk,"The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $253, $258, and $294 in 2021, 2020 and 2019.",$253,MONEY,"The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $253, $258, and $294 in 2021, 2020 and 2019.","['aggregate intrinsic value of options', 'cumulative difference between fair market value', 'fair market value of underlying common stock', 'aggregate intrinsic value', 'cumulative difference', 'fair market value', 'common stock']","['aggregate intrinsic value of options', 0.3472714126110077, 'What is $253 ?', 'aggregate intrinsic value of options']",aggregate intrinsic value of options,0.3472714126110077,What is $253 ?,aggregate intrinsic value of options,"Intrinsic value of options

Entity:
$258
Phrase:
Cumulative difference between fair market value of underlying common stock and option exercise prices

Entity:
$294
Phrase: 
Options exercised"
